MedTrace Logo

Myfortic for the Treatment of Non-infectious Intermediate Uveitis

NCT01092533 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2017-05-09

No results posted yet for this study

Summary

The objective of this clinical trial is to evaluate the efficacy, safety and tolerability of enteric-coated mycophenolate sodium (Myfortic®) in combination with low-dose corticosteroids (Decortin H®) compared to a monotherapy with low-dose corticosteroids (Decortin H®) in subjects with chronic intraocular inflammation (non-infectious intermediate uveitis).

Conditions

  • Uveitis, Intermediate

Interventions

DRUG

Myfortic

Myfortic 360 mg BID (during week 1) Myfortic 720 mg BID (from week 2 on) Maintenance dose Decortin 5mg/d

DRUG

Decortin

Maintenance dose 5 mg/d

Sponsors & Collaborators

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • University Hospital Tuebingen

    collaborator OTHER

  • STZ eyetrial

    lead OTHER

Principal Investigators

  • Christoph Deuter, Dr. · Centre for Ophthalmology, University of Tuebingen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01092533 on ClinicalTrials.gov